Abraxis Splits Injectable Generics Business Into Separate Unit
This article was originally published in The Pink Sheet Daily
Executive Summary
Abraxis CEO says the separation will allow the research business to focus more on personalized medicine.
You may also be interested in...
Strong Abraxane Cancer Data Promised, But Abraxis Mum On Spin-Off Details
Veteran Merck scientist recruited for personalized-medicine push.
Strong Abraxane Cancer Data Promised, But Abraxis Mum On Spin-Off Details
Veteran Merck scientist recruited for personalized-medicine push.
Abraxane vs. Taxotere: Abraxis Prepares To Go Head-To-Head In Phase III Trials
Study comparing Abraxane to Sanofi’s Taxotere for first-line breast cancer will start in second half, along with lung cancer and melanoma studies.